Syncona Limited (SYNC.L)
| Previous close | 212.00 |
| Open | 211.58 |
| Bid | 213.00 x 0 |
| Ask | 214.00 x 0 |
| Day's range | 210.50 - 214.09 |
| 52-week range | 161.60 - 272.49 |
| Volume | |
| Avg. volume | 673,952 |
| Market cap | 1.424B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -32.30 |
| Earnings date | 11 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Jun 2019 |
| 1y target est | 271.00 |
- The Telegraph
Pension funds must invest in UK biotech, says Syncona boss
Sitting in a tiny room in the bowels of the gigantic Wellcome Trust building in London, there must have been a brief moment when Martin Murphy questioned his life choices. It was 2012 and he had just left his comfortable career in venture capital to help the Wellcome Trust write the blueprint for a completely new type of company. “It was a handshake deal with Bill Castell, who was the chairman of Wellcome,” the 52-year-old recalls. “I turned up and it was me on my own in this little cupboard – w
- The Telegraph
Questor: this biotech pioneer has the potential for explosive gains – it’s one to lock away
Not many investment trusts tipped by this column describe their purpose as to “extend and enhance human life”. But that is the ambition of Syncona, the life sciences investor Questor tipped nearly two years ago, and it is not the only way it differs from most other trusts. Questor recommended Syncona as an alternative to the disastrous Woodford Patient Capital trust, and those who followed our advice in October 2019 have at least avoided further losses. Back then Questor feared that shares in Pa
